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A major ceramide monohexoside (CMH) was purified from lipidic extracts of Cryptococcus neoformans. This
molecule was analyzed by high-performance thin-layer chromatography (HPTLC), gas chromatography cou-
pled with mass spectrometry, and fast atom bombardment-mass spectrometry. The cryptococcal CMH is a
b-glucosylceramide, with the carbohydrate residue attached to 9-methyl-4,8-sphingadienine in amidic linkage
to 2-hydroxyoctadecanoic acid. Sera from patients with cryptococcosis and a few other mycoses reacted with the
cryptococcal CMH. Specific antibodies were purified from patients’ sera by immunoadsorption on the purified
glycolipid followed by protein G affinity chromatography. The purified antibodies to CMH (mainly immuno-
globulin G1) bound to different strains and serological types of C. neoformans, as shown by flow cytofluorimetry
and immunofluorescence labeling. Transmission electron microscopy of yeasts labeled with immunogold-
antibodies to CMH and immunostaining of isolated cell wall lipid extracts separated by HPTLC showed that
the cryptococcal CMH predominantly localizes to the fungal cell wall. Confocal microscopy revealed that the
b-glucosylceramide accumulates mostly at the budding sites of dividing cells with a more disperse distribution
at the cell surface of nondividing cells. The increased density of sphingolipid molecules seems to correlate with
thickening of the cell wall, hence with its biosynthesis. The addition of human antibodies to CMH to crypto-
coccal cultures of both acapsular and encapsulated strains of C. neoformans inhibited cell budding and cell
growth. This process was complement-independent and reversible upon removal of the antibodies. The present
data suggest that the cryptococcal b-glucosylceramide is a fungal antigen that plays a role on the cell wall
synthesis and yeast budding and that antibodies raised against this component are inhibitory in vitro.
Cryptococcus neoformans is a pathogenic fungus commonly
associated with immunocompromised hosts. The cryptococcal
infection follows the inhalation of fungal basidiospores (63) or
of poorly encapsulated yeasts (30). Infection is limited to the
lung or can disseminate to other tissues. In patients with ad-
vanced human immunodeficiency virus (HIV) infection, it
gives rise to a most serious, often fatal, meningoencephalitis.
The ability of C. neoformans to escape host defenses and
cause disease is closely associated with the production and
secretion of capsular polysaccharides, namely, the glucuron-
oxylomannan (GXM), galactoxylomannan, and mannoprotein
antigens. GXM, the major capsular polysaccharide of C. neo-
formans, is antiphagocytic, inhibits both the recruitment of
inflammatory cells and the increased expression of costimula-
tory molecules, suppresses delayed-type hypersensitivity, and
may reduce antibody production in response to fungal infec-
tion (reviewed in reference 44). In addition, C. neoformans
produces other factors clearly related to pathogenicity, such as
mannitol (65) and melanin (64). Additional cryptococcal mol-
ecules and enzymatic activities, such as sialic acids (45), phos-
pholipase (5), superoxide dismutase (22), and proteinase (4),
have been described with suggested, but still unclear, roles in
the infectious process.
Glycosphingolipids (GSLs) are conspicuous membrane con-
stituents of mammalian cells, protozoa, and fungi. Their hy-
drophobic ceramide moiety is linked to one or more sugars,
with the ceramide monohexosides (CMH) commonly having
glucose or galactose in both anomeric configurations. GSLs
of various sizes are involved in many processes such as cell-cell
interaction (19), mediation of apoptotic signaling (29), im-
munosuppression in cancer patients (28), and adhesion of fun-
gal pathogens to mammalian cells (18, 23). GSLs are also
implicated in cell growth, since the inhibitor of glucosylcer-
amide synthase, D-threo-1-phenyl-2-decanoylamine-3-morpho-
lino-propanol, abolished neurite outgrowth in the PC12 cell
line (36). The ceramide moiety of GSLs has been reported to
modulate growth of human (3) and fungal (14) cells.
Antibodies are highly relevant in the human protection
against cryptococcosis (11). In animal hosts, protective, non-
protective, and disease-enhancing monoclonal antibodies
(MAbs) against GXM have been described. Protection by anti-
GXM antibodies against the experimental infection by differ-
ent routes with several strains of C. neoformans was obtained
when these antibodies were administered alone or in conjunc-
tion with antifungal agents (42).
In the present work, we identified a major cryptococcal GSL
with a structure similar to CMH described in other fungal
pathogens (9, 26, 55, 56, 60). This molecule contains glucopy-
ranose b-linked to the ceramide moiety consisting of 9-methyl-
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4,8-sphingadienine in amidic linkage to 2-hydroxyoctadecanoic
acid and is accumulated mainly on the fungal cell wall. Sera
from patients with cryptococcosis recognize the cryptococcal
CMH. The reactivity of antibodies to CMH against both acap-
sular and encapsulated strains of C. neoformans was investi-
gated. Results show that these antibodies arrest fungal growth
in vitro presumably by interfering with the cell wall synthesis
and yeast budding.
MATERIALS AND METHODS
Chemicals. Culture media were obtained from Difco Laboratories (Detroit,
Mich.). Organic solvents and the chromatographic apparatus were purchased
from Merck (Rio de Janeiro, Brazil). Polyvinylidene difluoride (PVDF) mem-
branes, enzyme-linked immunosorbent assay (ELISA) plates, secondary antibod-
ies, and other reagents used for immunofluorescence and flow cytometry were
obtained from Sigma Chemical Co. (St. Louis, Mo.). Protein G-Sepharose 4 Fast
Flow was purchased from Amersham Pharmacia Biotech. Sera from patients
with different mycoses were kindly provided by Marcio Nucci, Hospital Univer-
sitario Clementino Fraga Filho, Rio de Janeiro, and Rosely Zancope, Labora-
torio de Micologia Me´dica, Hospital Evandro Chagas, FIOCRUZ, Rio de Ja-
neiro, Brazil.
Fungal strains. C. neoformans HEC3393 (serotype A, clinical isolate), CN23/
10.993 (serotype B, environmental isolate), and HEC40143 (serotype C, envi-
ronmental isolate) were obtained from Laborato´rio de Micologia Me´dica, Hos-
pital Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil. The strains ATCC
28597 (serotype D) and cap 67 (acapsular) were obtained from the American
Type Culture Collection. Stock cultures were maintained in Sabouraud dextrose
agar under mineral oil and kept at 4°C. For lipid extraction, immunofluores-
cence, electron microscopy, and flow cytometry, C. neoformans cells were culti-
vated in brain heart infusion (BHI) at room temperature for 5 days and then
separated by centrifugation and washed twice in 0.01 M phosphate-buffered
saline (PBS; pH 7.2).
Glycolipid extraction and purification. GSLs from yeast cells of C. neoformans
HEC3393 were extracted at room temperature successively with chloroform-
methanol 2:1 and 1:2 (vol/vol) (60). The crude lipid extract was partitioned
according to the method of Folch et al. (16). The lipids recovered from Folch’s
lower phase were fractionated on a silica gel column eluted with chloroform,
acetone, and methanol. The glycolipid fraction eluted with acetone was purified
by another round of silica gel column chromatography. This column was eluted
sequentially with the following mixtures: chloroform-methanol (95:5, 9:1, 8:2,
and 1:1 [vol/vol]) and finally methanol alone. The purified GSL fraction obtained
in the chloroform-methanol 9:1 (vol/vol) fraction was analyzed by high-perfor-
mance thin-layer chromatography (HPTLC), developed with chloroform-meth-
anol-water 65:25:4 (vol/vol). The spots were visualized with iodine and by spray-
ing with orcinol-H2SO4.
Sugar analysis. The purified glycosphingolipid fraction was hydrolyzed in 0.5
M sulfuric acid at 100°C for 18 h, and the resulting monosaccharides were
identified as their alditol acetates on a Hewlett-Packard 5890 gas chromatograph
equipped with a fused silica capillary (25 by 0.22 mm) OV-225 (50% cyanopro-
pylmethyl, 50% phenylmethyl-polysiloxane) column. A temperature program of
180°C held isocratically for the first 15 min and then elevated to 210°C at 2°C/min
was used. The analysis was monitored with a flame-ionization detector.
Fatty acid analysis. The fatty acid portion of the cryptococcal GSL was char-
acterized by gas chromatography coupled with mass spectrometry (GC-MS).
Fatty acid methyl esters were obtained by incubating the purified GSL overnight,
at 70°C, in the presence of toluene-methanol (1:1, vol/vol) containing 2.5%
concentrated sulfuric acid. The sample was diluted in water and extracted twice
with hexane-chloroform (4:1, vol/vol). The combined extracts were dried by
vacuum centrifugation, and the trimethylsilyl derivatives were prepared with
bis(trimethylsilyl)trifluoroacetamide-pyridine (1:1, vol/vol) for 30 min at 60°C.
Samples were dried by vacuum centrifugation and analyzed in a Kratos MS80
RFA spectrometer directly interfaced to a Carlo Erba 5160 chromatograph.
Samples were introduced by splitless injection (splitless time, 30 s) into a BPX-5
FIG. 1. Isolation and purification of C. neoformans glucosylceramide. Steps of purification (left) and their corresponding fractions (right) are shown. Abbreviations
are as defined in the text.
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fused silica column (25 m by 0.2 mm; SGE, Milton Keynes, United Kingdom).
The injector and interface oven were maintained at 250°C. One minute after
injection, the oven temperature was programmed from 60 to 200°C at 40°C/min
and then at a rate of 3°C/min to 230°C, with a final 8°C ramp to 265°C. This
temperature was maintained for 10 min. Electron ionization spectra were re-
corded at an ionization energy of 70 eV, trap current of 100 mA, and a source
temperature of 220°C.
Structural elucidation of the cryptococcal glycolipid. For structural analysis of
the cryptococcal glycolipid, fast atom bombardment-mass spectrometry (FAB-
MS) was used. The underivatized cryptococcal GSL and its peracetyl derivative
were analyzed in a Kratos MS80 spectrometer as previously described by Duarte
and coworkers (9).
Reactivity of CMH with patients’ sera. The reactivity of the cryptococcal
glucosylceramide with sera from patients with cryptococcosis, aspergillosis, his-
toplasmosis, and paracoccidioidomycosis was evaluated by using ELISA as de-
scribed by Villas-Boas et al. (61) with minor modifications. The GSL was dis-
solved in methanol (200 mg/ml), and 50 ml of this solution was added per well to
a flat-bottomed polystyrene microtiter plate. The plate was dried, and blocked
with PBS containing 10% bovine serum albumin (BSA) for 1 h at 37°C. After a
washing with PBS, 50 ml of normal human sera or sera from patients, diluted 1:50
in PBS, was added to each of the coated wells and incubated at 37°C for 1 h. The
plate was washed three times prior to incubation with peroxidase-labeled goat
anti-human immunoglobulin (1:2,000) for 1 h at 37°C. The plate was again
washed three times with PBS, and 50 ml of o-phenylenediamine in citrate-
phosphate buffer containing H2O2 was added to each well, followed by incuba-
tion in the dark and reading at 492 nm.
The relative participation of antibodies to CMH in the reaction of cryptococcal
antigens and sera of patients with cryptococcosis was evaluated by comparing the
reactivities of a pool of five sera with a crude fungal extract before and after
depletion of antibodies to CMH. The crude extract of strain HEC3393 was
obtained from a thick suspension of C. neoformans cells in a lysis buffer (0.01 M
PBS, pH 7.4; 1% Triton X-114; 1 mM EDTA; 1 mM E-64; 5 mM dithiothreitol;
1 mg of aprotinin per ml; 1 mg of pepstatin per ml). An equivalent volume of glass
beads (0.3 mm in diameter) was then added to the suspension, and yeasts were
broken in a cell disrupter (type 853023/8; B. Braun Biotech International, Ger-
many) by alternating 1-min shaking periods and 2-min cooling intervals. After
removal of the glass beads, the suspension was centrifuged (10,000 3 g, 30 min,
4°C). The total protein of the crude extract was determined by the method of
Lowry et al. (27) and adjusted to 200 mg/ml for use in ELISA reactions.
Purification of antiglucosylceramide antibodies. The purified cryptococcal
glucosylceramide (500 mg) was dissolved in 50 ml of methanol and spotted onto
a strip of PVDF membrane, which was blocked with PBS containing 0.1% Tween
20 and 10% BSA for 2 h at room temperature. The membrane was washed four
times in PBS-Tween and then incubated overnight at 4°C in the presence of a
pool of five sera (at 1:2) obtained from patients with cryptococcosis. After
repeated washing to remove unbound proteins, bound antibodies were eluted
using 2 ml of 100 mM glycine acid buffer (pH 3.0) and immediately neutralized
with 1 M Tris-HCl (pH 9.0). This process was repeated three times, and the
unbound depleted fraction contained antibodies that gave absorbance readings
by ELISA similar to those with normal human serum (NHS) at the same low
dilution. Eluted samples were further purified in protein G-Sepharose 4 Fast
Flow, according to the manufacturer’s protocol. Fractions containing antibodies
to CMH were ultrafiltered in a Centricon-10 micropartition system from Amicon
and concentrated by vacuum centrifugation. The recovery of antiglucosylceram-
ide antibodies was monitored by analyzing the eluted samples by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting
with a monoclonal peroxidase-labeled anti-human antibody. As a control, the
CMH-bound PVDF membrane was incubated overnight at 4°C in the presence
of normal human immunoglobulin G (IgG). Bound antibodies, eluted with gly-
cine buffer (pH 3.0), were immediately neutralized with 1 M Tris-HCl (pH 9.0)
and then combined with the unbound antibody fraction and purified in protein
G-Sepharose.
Flow cytometry analysis. Capsulated (HEC3393) and noncapsulated (cap 67)
C. neoformans cells were fixed in 4% paraformaldehyde cacodylate buffer (0.1 M,
pH 7.2) for 1 h at room temperature. Fixed yeast cells were washed twice in PBS
and incubated sequentially for 30 min in PBS containing 150 mM NH4Cl and
then in 1% BSA in PBS (PBS-BSA) for 1 h. Yeast cells (106/ml) were washed in
PBS and sequentially incubated with antibodies to CMH (at 1:10 dilution) and
fluorescein isothiocyanate (FITC)-labeled anti-human IgG (at 1:100 dilution) for
1 h at room temperature. Yeasts were again washed, and 5,000 cells were
analyzed in an EPICS ELITE flow cytometer (Coulter Electronics, Hialeah, Fla.)
equipped with 15-mW argon laser emitting at 488 nm. Data were obtained using
listmode, which makes further analysis possible. Control cells were incubated
with the fluorescein conjugate but not with antiglucosylceramide antibodies.
Immunofluorescence analysis. Cryptococcal yeasts from different serotypes
(HEC3393, CN23/10.993, HEC40143, ATCC 28597, and cap 67 strains) were
fixed and blocked as described for flow cytometry and incubated in the presence
of the antibody preparations at 1:10 dilution for 1 h (acapsular cells) or 12 h
(encapsulated cells) at room temperature. After incubation, the cells were
washed three times in PBS and incubated with FITC-labeled anti-human IgG at
1:100 for 1 h at room temperature (acapsular cells) or 24 h at 4°C (encapsulated
cells). Control cells, which had not been incubated with antiglucosylceramide
antibodies, were also prepared. Cells were washed and, for microscopic exami-
nation, 5 ml of a cell suspension at 107 yeasts/ml containing FITC-labeled-
antibody-treated C. neoformans was placed on glass slides and observed with
Axioplan 2 (Zeiss) fluorescence microscope. Acapsular cells, which showed the
FIG. 2. GC-MS analysis of the fatty acid moiety obtained from hydrolysis of the cryptococcal glucosylceramide. A single peak corresponding to a hydroxylated fatty
acid was detected (inset), identified as 2-hydroxy-octadecanoic acid. For interpretation of the fragmentation, see Results.
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most intense reaction, were also evaluated by confocal microscopy in a Zeiss
LSM 410 Inverted confocal laser-scanning microscope, with the LSM software.
Computer-generated images were finally edited using Adobe Photoshop version
4.0, which included color, brightness, and contrast adjustment.
HPTLC-immunostaining. C. neoformans var. neoformans (serotype D) or gattii
(serotype B) were extracted and partitioned as described above. The Folch’s
inferior phases were then separated by HPTLC, the plate being air dried, soaked
in 0.5% polymethacrylate in diethyl ether, and blocked for 2 h with 10%
skimmed milk in PBS. The plate was then incubated for 2 h in presence of the
preparation of antibodies to CMH (at 1:10 dilution), followed by sequential
incubation with peroxidase-conjugated anti-human antibody and diaminobenzi-
dine, as described elsewhere (51). As a positive control, the purified glucosylce-
ramide from whole cryptococcal cells (strain HEC3393) was used.
Lipid extraction from cell wall preparations. To determine whether the cryp-
tococcal CMH is cell wall associated, cell wall preparations of C. neoformans (cap
67) were obtained as previously described (43). Cryptococcal yeasts were mixed
with glass beads and broken in a cell disrupter (type 853023/8; B. Braun Biotech
International). The glass beads were removed, and the suspension centrifuged at
2,000 3 g for 10 min at 4°C. The pellet containing the cell wall fragments was
suspended in distilled water, homogenized, and centrifuged at 16,000 3 g for 15
min. This step was repeated 50 times, and the final cell wall preparation extracted
with chloroform-methanol at 2:1 and at 1:2 (vol/vol) (60). The cell wall lipid
extract was partitioned according to the method of Folch et al. (16), and the
inferior phase was analyzed by HPTLC or HPTLC-immunostaining, as described
above.
Immunogold labeling of cryosections. Cryptococcal yeasts (strain cap 67) were
fixed for 1 h in 0.1 M sodium cacodylate buffer (pH 7.2) containing 4% para-
formaldehyde and 2% glutaraldehyde. Cells were then infiltrated for 2 h in a
solution containing 25% polyvinylpyrrolidone and 2.1 M sucrose and rapidly
frozen by immersion in liquid nitrogen. They were transferred to a cryoultrami-
crotome (Ultracut Reichert), and cryosections were obtained in a temperature
range of 270 to 290°C. The material was collected with a sucrose loop and
FIG. 3. FAB-MS of the peracetylated glucosylceramide from C. neoformans and its corresponding native structure. For interpretation of fragmentation, see Results.
FIG. 4. (A) Reactivity of CMH with patients’ antibodies. Sera from individuals with cryptococcosis (Cn), histoplasmosis (Hc), aspergillosis (Af), and paracoccid-
ioidomycosis (Pb) recognize the cryptococcal CMH, while sera from normal individuals (NHS) do not. (B) Reactivity of crude extracts (CE) of C. neoformans with a
pool of patients’ serum ( n ) and patients’ serum depleted of antibodies to CMH (h).
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transferred to Formvar-carbon-coated grids. For immunolabeling the cryosec-
tions were incubated for 15 min in PBS containing 3% BSA, quenched for 30 min
in 50 mM NH4Cl, and subsequently incubated overnight in the presence of
purified antibodies to CMH (1:20 dilution). Grids were then washed twice with
PBS-BSA and incubated for 1 h in the presence of 15-nm (particle size) immu-
nogold-labeled anti-human IgG (1:100 dilution). Samples were then washed in
PBS containing decreasing concentrations of BSA (3, 2, and 1%) and thinly
embedded in 3% polyvinyl alcohol-uranile acetate (9:1, vol/vol). Specimens were
finally observed in a Zeiss 900 transmission electron microscope operating at 80
kV.
Antibody specificity. The possibility of cross-reactions between antibodies to
CMH and fungal cell wall components was evaluated by ELISA. Cryptococcal
CMH was added to a flat-bottomed polystyrene microtiter plate as described
above and incubated in the presence of antibodies to CMH. The following
components and preparations were tested as inhibitors of the reaction between
CMH and antibodies to this glycolipid: (i) an alkaline-soluble extract from
lipid-free C. neoformans cell walls prepared as previously described (2), (ii)
N,N,N,N-tetraacetylchitotetraose ([GlcNAc]4), (iii) mannan from Saccharomyces
cerevisiae, (iv) b-gentibiose (glucosyl-b-1,6-glucose); (v) laminarin (mostly linear
b-1,3-glucan); and (vi) zymosan A; all were used at 1 mg/ml. Control systems
consisted of protozoan cruzipain (a gift from Julio Scharfstein)–anti-cruzipain
MAb and human IgG–anti-human IgG antibody.
Cell growth. To evaluate the influence of antibodies to CMH on cell growth
and budding, 106 yeast cells from strains HEC3393 or cap 67 of C. neoformans
were inoculated in sterile microcentrifuge tubes containing 500 ml of BHI sup-
plemented with 20% of NHS or 20% of heat-inactivated NHS (triplicate sets).
Purified antibodies to CMH were added at 10 mg/ml, 10-ml aliquots from each
culture were taken at 12-h intervals, and the total numbers of cells in these
suspensions as well as the numbers of budding cells were counted in a Neubauer
chamber. Control systems had either no antibodies added or normal human IgG
(100 mg/ml), prepared as described above. To evaluate the ability of antibodies
to CMH to kill cryptococci, HEC3393 cells were first cultivated in the presence
of these antibodies for 72 h in BHI supplemented with normal or heat-inacti-
vated NHS. The antibody-containing culture medium was then replaced by BHI,
and the yeasts were cultivated for 168 h. At 24-h intervals, the cell numbers in
10-ml aliquots of the cultures were counted in a Neubauer chamber.
RESULTS
Purification and identification of GSL. The purification
steps of GSLs from C. neoformans cells (strain HEC3393) are
shown in Fig. 1. A single orcinol-reactive band was detected by
HPTLC, with an Rf similar to that of a standard CMH from
bovine brain. The monosaccharide was identified as glucose by
gas chromatography (data not shown). For fatty acid analysis,
the cryptococcal CMH was methanolysed, trimethylsilylated,
and examined by GC-MS. A single peak (Fig. 2) provided a
mass spectrum with a weak molecular ion (M) at a mass-to-
charge (m/z) of 386, an ion at m/z 371 (M-15), and a base peak
at m/z 327 (M-29). The latter fragment, which originated from
cleavage between the carboxyl group and carbon 2, is charac-
teristic of 2-hydroxy fatty acid methyl esters (10, 46), which
allowed us to identify the compound as 2-hydroxy-octadeca-
noic acid.
The negative-ion FAB spectrum of the underivatized CMH
from C. neoformans (not shown) revealed an abundant ion at
m/z 754, which is consistent with the deprotonated molecule of
a monohexosylceramide containing hydroxyoctadecanoic acid
and C19 sphingadienine. A fragment at m/z 592 represents loss
of hexose via a Y-type process (8). These data were confirmed
by FAB-MS of the peracetylated glycolipid (Fig. 3). The [M 1
Na]1 signal observed at m/z 1030 indicated the addition of six
acetyl groups to the mass of the underivatized glycolipid, which
is consistent with a hydroxy acid containing CMH. Another ion
was detected at m/z 948 (M 1 H-HOAc [HOAc, acetic acid]).
The abundant ion detected at m/z 331 indicated the presence
of a terminal hexose; the fragment at m/z 229 was attributed to
the loss of ketene plus acetic acid from m/z 331, and further
elimination of acetic acid gave m/z 169. Peaks at m/z 660
(CerAc2
1 [diacetylated ceramide]), 600 (CerAc2
1 2 HOAc),
and 540 (CerAc2
1 2 2HOAc) identified the ceramide moiety.
The fragment at m/z 276, which is diagnostic of a C19 sphin-
gadiene (9), originates from the long-chain base.
Reactivity of the cryptococcal glucosylceramide with pa-
tients’ antibodies. The purified cryptococcal CMH reacted
with sera from five patients with cryptococcosis (Fig. 4A). Sera
from patients with histoplasmosis, aspergillosis, and paracoc-
cidioidomycosis also recognized the cryptococcal CMH, indi-
cating that antibodies against similar structures are produced
during the course of these mycoses. The reactivity of crude
multiantigenic extracts of C. neoformans with patients’ sera or
with sera that had been depleted of antibodies to CMH by
immunoadsorption showed that the latter represented ca. 10%
of the total serum reactivity (Fig. 4B).
Immunofluorescence. Antiglucosylceramide antibodies were
obtained from the sera of patients with cryptococcosis, which
were pooled, immunoadsorbed on the solid-phase fixed glu-
cosylceramide, and finally purified by affinity chromatography.
Acid-eluted antibodies were mainly IgG, as monitored by SDS-
PAGE and Western blotting. The predominant isotypes were
IgG1 @ IgG4 . IgG3 (not shown). These antibodies were
incubated with encapsulated and acapsular C. neoformans cells
and analyzed by flow cytofluorimetry, as shown in Fig. 5. On
short incubation (1 h), the reaction of encapsulated cells with
antiglucosylceramide antibodies was absent or very weak. In
contrast, the acapsular population readily reacted with the
antiglucosylceramide antibodies, with a shift of the fluores-
cence peak. Immunofluorescence microscopy (Fig. 6), under
the same conditions as those described above, also showed no
detectable reaction of encapsulated cells with antibodies to
CMH (data not shown), whereas the acapsular yeasts showed
uniform surface labeling of mature nondividing cells. The flu-
orescent labeling was rather concentrated at the sites of bud-
ding in dividing cells (Fig. 6B). Encapsulated cells were then
incubated with the antibodies for longer periods, which al-
lowed the detection of positive fluorescent reactions at the
yeast budding sites and on young daughter and nondividing
cells (Fig. 6D, F, H, and J). Cells were heterogeneously immu-
nostained, with intense and poor labeling being observed on
the same microscopic field. Acapsular cells, which were more
strongly reactive, were examined by confocal microscopy,
which showed that the distribution of the glucosylceramide in
mature cells was in small aggregates on the cell surface (Fig.
7A and B). In dividing cells the budding sites seemed to accu-
mulate most of the antibody-reactive CMH as if the glycolipid
clusters were part of the underlying structure where the cell
FIG. 5. Flow cytometric analysis of encapsulated (HEC3393) and acapsular
(cap 67) C. neoformans yeast cells incubated with antiglucosylceramide antibod-
ies. Data curves: a, control cells (no antiglucosylceramide antibodies were added
prior to incubation with FITC-labeled anti-human IgG); b, incubation of C.
neoformans with antiglucosylceramide antibodies. After 1 h of exposure, the
acapsular but not the encapsulated cells were reactive.
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wall is synthesized for bud formation. The use of the LSM
software allowed us to overlay the specific fluorescent reaction
of CMHs with antibodies to CMH and the autofluorescence of
the thickened cryptococcal cell wall at the site of bud emer-
gence (Fig. 7C and D). In general, the CMH reactions seemed
to coincide with cell wall thickening.
Immunostaining. Lipid extracts from whole C. neoformans
cells, as well as from cell wall preparations, were obtained and
partitioned according to the method of Folch and coworkers
(16). The lower layers were then analyzed by HPTLC and
HPTLC-immunostaining. Orcinol-reactive bands with Rf val-
ues similar to that of the purified CMH were detected in
extracts from C. neoformans var. neoformans (Fig. 8A) or gattii
and from cell wall preparations. These bands were recognized
by antibodies to CMH (Fig. 8B), confirming that CMH is
produced by different varieties and serotypes of C. neoformans.
FIG. 6. Surface distribution of the cryptococcal glucosylceramide. Acapsular (A and B) and encapsulated (C to J) C. neoformans yeast cells were incubated in the
presence of antiglucosylceramide antibodies, followed by incubation with FITC-labeled anti-human IgG and observed in a fluorescence microscope. In control systems,
in which no antiglucosylceramide antibodies were added prior to incubation with FITC-labeled anti-human IgG, no detectable fluorescence was observed (not shown).
The left panels show C. neoformans yeasts using differential interferential contrast microscopy. Panels: A and B, acapsular cells; C and D, cryptococci of serotype A;
E and F, serotype B cells; G and H, serotype C cells; and I and J, serotype D cells. Bar, 10 mm.
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Additionally, this analysis suggested that CMH molecules
make part of the fungal cell wall components.
Cryptococcal CMH is cell wall associated. To confirm the
subcellular sites of CMH accumulation, cryosections of C. neo-
formans cells (cap 67) were processed for transmission electron
microscopy using immunogold labeling. By using this tech-
nique we showed extensive antibody binding to the cryptococ-
cal wall (Fig. 9A), including the cell wall structures that had
detached from the cell during processing. Only a few gold
particles were seen on the membrane and a few more were
found in the periplasmic space. Points of transport of the
presumed CMH-containing vesicles from the plasma mem-
brane to the cell wall were also suggested (Fig. 9B). To exclude
the possibility that the strong reaction with antibodies to CMH
was due to cross-reaction with known cell wall components,
delipidated cell wall extracts and molecules commonly found
in fungal walls were tested as inhibitors of the antigen-antibody
interactions in ELISA. Of these, only laminarin was partially
effective in inhibiting the reaction of CMH and antibodies to
CMH (Table 1). The specificity of this inhibition was, however,
doubtful, since laminarin also inhibited binding of a monoclo-
nal anticruzipain antibody to protozoan cruzipain as well as
that of anti-human IgG antibodies to human IgG, which were
used as control systems.
Antibodies to CMH inhibit cell budding and growth. To
clarify the involvement of CMH in the cell budding of C.
neoformans, antibodies to CMH were added to cryptococcal
cultures, and the number of cryptococci determined at 12-h
intervals. The growth of C. neoformans cells in the presence of
antibodies to CMH was quantified and compared to the cryp-
tococcal growth in the absence of antibodies or in the presence
of normal human IgG, used as a negative control. The addition
of antibodies to CMH to the cultures clearly inhibited fungal
growth (Fig. 10A) either of acapsular or encapsulated cells.
The inhibitory effect was observed after 24 h in the culture of
the acapsular strain, whereas a longer period, 36 h, was nec-
essary for a similar inhibition of the encapsulated strain. Seem-
ingly, the capsule in C. neoformans retards the diffusion of
antibodies to the cell surface of this fungus. The number of
budding cells, as well as the number of buds per cell, in both
acapsular and encapsulated cells was similarly reduced by re-
action of the CMH-rich structures with antibodies to CMH
(Fig. 10B). The inhibitory effect of these antibodies was not
complement dependent, since similar growth rates were ob-
served when C. neoformans cells were cultivated in the pres-
ence of NHS or heat-inactivated NHS. Additionally, antibodies
FIG. 7. Confocal microscopy of CMH at the cell surface of acapsular C.
neoformans cells. (A to C) Budding cells show the CMH (arrows), mainly con-
centrated at the budding region, while mature nondividing cells have some
weakly labeled clusters on the cell surface. (D) Cells shown in Fig. 7C were
analyzed by overlaying the specific fluorescent reaction of surface CMH with
antibodies to them (arrows) and the autofluorescence of the cryptococcal cell
wall (blue). This technique shows that the polar concentration of CMH colocal-
izes with a thickened cell wall to the site of bud formation. Autofluorescence of
the nucleus is shown in red. Bars, 1 mm.
FIG. 8. HPTLC (A) and HPTLC-immunostaining (B) of glycolipids obtained from serotype B (lanes a) and D (lanes b) cells or from cell wall preparations from
cap 67 cells (lanes c) compared with the purified glucosylceramide from HEC3393 cells (lanes d). Orcinol-reactive bands with Rf values similar to that of the purified
cryptococcal glucosylceramide were detected by HPTLC. Immunostaining showed that antibodies to CMH recognized components with migration similar to that of
CMH.
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raised against CMH did not kill C. neoformans, since yeast
growth resumed after replacement of the antibody-containing
media by BHI (Fig. 11).
DISCUSSION
GSLs have been characterized in fungal and protozoan
pathogens (1, 9, 54–56, 59–61). Although the biological func-
tions of these molecules are not fully understood, they were
shown to be antigenic in different infectious agents. For in-
stance, GSLs from Trypanosoma cruzi epimastigotes react with
sera from patients with Chagas’ disease, and this reactivity is
modulated by the ceramide structure (61). Schistosome glyco-
lipids are recognized by IgE, which may have a role in immu-
nity against Schistosoma mansoni (57). A glucosylceramide is
the major GSL from the opportunistic pathogen Pseudoall-
escheria boydii (41) and, as with C. neoformans glycolipid, is
recognized by sera from infected individuals. In Paracoccid-
ioides brasiliensis, a galactofuranose-containing GSL is reactive
with antibodies from patients with paracoccidioidomycosis
(54). Such reactivity was attributed to the nonreducing galacto-
furanosyl residue in the carbohydrate chain. b-Glucopyranosyl
ceramides (GlcCer) with 29-OH-fatty acids, or GlcCer and
b-galactosyl ceramide, were characterized in P. brasiliensis and
Aspergillus fumigatus, respectively (56). In C. neoformans, the
major sphingolipids described previously consisted of cer-
amide, inositol, and mannose (62). In a recent work, Franzot
and Doering (17) described the synthesis of glycosylphosphati-
dylinositol (GPI) anchors in membranes of cryptococcal yeasts.
The relevance of the cryptococcal b-glucosylceramide was
addressed in the present work. The possible involvement of
this molecule in fungal pathogenicity was hypothesized, since
human antibodies against this CMH were isolated from sera of
patients with cryptococcosis by immunoadsorption on the pu-
rified glycolipid and by affinity chromatography. They inhibited
C. neoformans budding and growth. The presence of CMH as
structural components of the cryptococcal cell wall was dem-
onstrated by electron microscopy of yeast cells labeled with
immunogold-antibodies to CMH. Abundant deposition of gold
particles was observed on the cryptococcal wall rather than on
the plasma membrane. Apparently, the antibody-reactive
epitopes of CMH may be sterically accessible only after trans-
fer of the GSLs to the cell wall. Labeling was observed on
membrane formations (vesicles?) across the periplasmic space,
linking the plasma membrane to the inner face of the cell wall
(Fig. 9B). Antibodies located the CMH preferentially to the
sites of cell budding, which suggests that this glycolipid is
essential for cellular division. A possible relationship of CMH
and the cell wall biosynthetic enzymes, particularly at the bud-
ding sites, could suggest a specific lipid requirement. Data
FIG. 9. Cryptococcal CMH are located at the fungal cell wall. (A) Transmission electron microscopy showed an extensive binding of antibodies to CMH to the
cryptococcal cell wall, integrated or detached from the cells. Bar, 0.5 mm. (B) Possible CMH-containing vesicles are seen (arrows), which can move across the
periplasmic space and deposit cell membrane constituents on the cell wall. Bar, 0.1 mm.
TABLE 1. Reactivity of cryptococcal CMH with human antibodies
to CMH in the presence of fungal cell wall componentsa
Cell wall componentsb at 1 mg/ml % Decrease in reactivity
N,N9,N99,N999-Tetraacetylchitotetraose...............6.6
Mannan (S. cerevisiae)..........................................7.2
b-Gentibiose ..........................................................0
C. neoformans cell wall alkaline extract
(neutralized to pH 7.0) ....................................0
Zymosan A ............................................................14.6
Laminarin...............................................................40.8 (anti-CMH), 43.3
(anti-cruzipain)c,
57.3 (anti-IgG)c
a ELISA of b-glucosylceramide at 10 mg/well and patients’ antibodies to CMH
diluted 1:50.
b Chitin and b-glucan-derived oligosaccharides, polysaccharides, and soluble
cell wall extracts incubated with the antibodies to CMH and added to the
CMH-coated plates.
c Inhibition by laminarin of the homologous systems with cruzipain–anti-cruz-
ipain MAbs and IgG–anti-IgG antibodies.
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from another system support this interpretation. Kawai et al.
(24, 25) showed that fungal glucocerebrosides had fruiting-
inducing activity in bioassays with Schizophyllum commune.
The intact 9-methyl-4,8-sphingadienine but not the b-glucopy-
ranosyl residue was essential for this activity.
Binding of lectins or antibodies to cell wall components can
interfere with the biosynthesis and organization of the cell wall
polymers. In Fusarium sp. (6), treatment with wheat germ
agglutinin, which has a known affinity for chitin, resulted in
alterations in germ tube formation and caused cell lysis. As a
consequence, fungal infection did not spread with lectin-
treated Fusarium. The inhibitory activity of antibodies to CMH
may involve a different mechanism. GSLs form, with sterols
and GPI-anchored proteins, detergent-insoluble lipid rafts on
the plasma membrane (35, 48, 67). They are required for the
processing of GPI-anchored proteins in yeasts, making part of
vesicles that link the RES to Golgi to the plasma membrane
(21, 50, 52). For the synthesis of the cell wall structural network
it has been proposed that GPI anchors have a pivotal consti-
tutive role (7). A truncated GPI anchor which no longer con-
tains inositol and glucosamine is the substrate for a phosphate-
linked b-1,6-glucan extension (49, 58). GPI anchors can be
liberated in the periplasmic space by the action of phospho-
lipase C (PI-PLC), as present in S. cerevisiae (15) and abun-
dantly expressed in P. brasiliensis (20), or could be transported
to the cell wall in vesicles. This may happen due to the inability
of GPI anchor cleavage by PI-PLC, a property of inositol-
acylated molecules found in C. neoformans (17), or to a more
generalized process in which precursor molecules and enzymes
are transferred to the cell wall in vesicles originating from the
FIG. 10. Influence of antibodies to CMH on the cell growth (A) and budding (B) of encapsular (a and b) and acapsulated (c and d) C. neoformans. The culture
medium was supplemented with NHS (a and c) or heat-inactivated NHS (HI-NHS, b and d). Addition of antibodies to CMH to the cell cultures at 10 mg/ml ()
inhibited fungal growth and budding in both acapsular and encapsulated cells. F, Untreated cells; n , cells treated with normal human IgG, processed as for the
antibodies to CMH, at 100 mg/ml.
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plasma membrane. Cell wall particles have been described in
C. neoformans (47) presumably containing precursors of the
capsule. Spherical invaginations which secrete vesicles outside
the cell membrane have also been well documented by Takeo
et al. (53) in C. neoformans using the freeze-etching technique.
Assuming then that GSLs closely associated with GPI precur-
sors as in lipid rafts and presumably also biosynthetic enzymes
are transported to the cell wall in vesicles, the action of anti-
bodies to CMH could impair the utilization and reactivity of
the carried components. Antibody inhibition of budding can
also be correlated with the increased secretion of enzyme-
containing vesicles during bud formation (31).
The role of antibody immunity against C. neoformans was
reviewed by Pirofski and Casadevall (42). Experiments with
polyclonal sera have produced conflicting evidence for and
against the importance of antibody immunity in host defense.
Accordingly, tests with MAbs to the C. neoformans capsular
polysaccharide have revealed the existence of protective, non-
protective, and disease-enhancing MAbs, suggesting that data
obtained in experiments with polyclonal preparations may be
explained by differences in the relative proportion of protective
and nonprotective antibodies in the immune sera. Mechanisms
by which protective MAbs would modify the course of infec-
tion were proposed based on in vitro experiments, in which
these antibodies enhanced effector cell functions against C.
neoformans (32–34). The complexity of antibody binding to
surface structures of C. neoformans as recently shown, using
three MAbs (12), does not warrant the assumption that cell
wall-reacting antibodies to CMH will be equally effective when
admixed with other anticryptococcal antibodies of different
specificity.
The relevance of the anti-CMH effect in vivo is under inves-
tigation. Antibodies to CMH should reach a plasma concen-
tration compatible with that minimally effective to inhibit cryp-
tococci in vitro. Purified human antibodies were inhibitory in
vitro at 10 mg/ml or at 5 pg/fungal cell, but lower concentra-
tions were not tested. The inhibition was specific since 10-fold-
more normal human IgG was inactive. Cryptococcal cells are
100% encapsulated in vivo (M. Feldmesser, personal commu-
nication); however, as shown here and previously, with anti-
melanin antibodies (38), IgG molecules diffuse through the
capsule to reach the cell surface, depending on their concen-
tration and time of exposure. The possibility that C. neofor-
mans can be a facultative intracellular pathogen (13) would
represent an efficient escape mechanism against antibodies to
CMH.
The cryptococcal b-glucopyranosyl ceramide is very similar
to other fungal cerebrosides in that they all contain a 9-methyl-
4,8-sphingadienine in combination with N-29-hydroxy fatty ac-
ids that are saturated or unsaturated (9, 26, 55, 56, 60).
Hydroxylation at position 2 of the fatty acid is apparently
important for antigenicity of the CMH (37, 66), and possible
epitopes involve both glucose and the hydroxylated fatty acid,
with modulation by the sphingosine-derived base. Conformer 4
of glucosylceramide as studied by Nyholm and Pascher (39,
40), which is allowed in a membrane layer and further stabi-
lized by a hydrogen bond between the 2-OH group on the fatty
acid and the 6-OH group on the glucose residue, in addition to
the hydrogen bond between glucose O5 and the amide hydro-
gen, is a candidate for carrying epitopes reactive with antibod-
ies to CMH. Antibodies to CMH elicited in patients with
cryptococcosis and also in patients with other mycoses as pres-
ently shown could inhibit the growth of pathogenic fungi that
express the same GSL, if accessible to the cell wall inner
structure and biosynthetic core. Preliminary results from our
laboratory indicate that in P. boydii, which also synthesizes a
b-glucosylceramide, antibodies to CMH inhibit formation of
germinative tubes and growth (E. Barreto-Bergter et al., un-
published results). A general fungistatic effect of antibodies to
CMH is thus suggested, which encourages the investigation of
their action against other mycopathogens.
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